ARWR (Arrowhead Pharmaceuticals) Cyclically Adjusted Book per Share: $3.43 (As of Mar. 2026)


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $79.62
GF Value $52.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share?

Arrowhead Pharmaceuticals ARWR +0.74% 49 Cyclically Adjusted Book per Share is $3.43 as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $52.13 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $4.368. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.43 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arrowhead Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 9.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Arrowhead Pharmaceuticals was 62.60% per year. The lowest was -38.70% per year. And the median was 4.10% per year.

As of today (2026-06-29), Arrowhead Pharmaceuticals's current stock price is $79.6175. Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $3.43. Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 23.21.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arrowhead Pharmaceuticals was 43.20. The lowest was 0.47. And the median was 11.00.


Arrowhead Pharmaceuticals  (NAS:ARWR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=79.6175/3.43
=23.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arrowhead Pharmaceuticals was 43.20. The lowest was 0.47. And the median was 11.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.42 2.89 3.25 3.16 3.26

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 3.21 3.26 3.30 3.43

ARWR vs CYTK, TECH, KRYS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.368/330.2130*330.2130
=4.368

Current CPI (Mar. 2026) = 330.2130.

Arrowhead Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.993 241.018 1.360
201609 1.370 241.428 1.874
201612 1.314 241.432 1.797
201703 1.256 243.801 1.701
201706 1.205 244.955 1.624
201709 1.089 246.819 1.457
201712 0.944 246.524 1.264
201803 1.305 249.554 1.727
201806 1.165 251.989 1.527
201809 1.082 252.439 1.415
201812 1.858 251.233 2.442
201903 2.125 254.202 2.760
201906 2.376 256.143 3.063
201909 2.561 256.759 3.294
201912 4.946 256.974 6.356
202003 4.856 258.115 6.212
202006 4.823 257.797 6.178
202009 4.511 260.280 5.723
202012 4.404 260.474 5.583
202103 4.283 264.877 5.339
202106 4.192 271.696 5.095
202109 3.919 274.310 4.718
202112 3.555 278.802 4.211
202203 4.279 287.504 4.915
202206 4.291 296.311 4.782
202209 3.761 296.808 4.184
202212 3.552 296.797 3.952
202303 4.181 301.836 4.574
202306 3.406 305.109 3.686
202309 2.529 307.789 2.713
202312 1.492 306.746 1.606
202403 3.897 312.332 4.120
202406 2.661 314.175 2.797
202409 1.491 315.301 1.562
202412 0.419 315.605 0.438
202503 4.949 319.799 5.110
202506 3.781 322.561 3.871
202509 3.434 324.800 3.491
202512 4.137 324.054 4.216
202603 4.368 330.213 4.368

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.43 mean?
Arrowhead Pharmaceuticals (ARWR) has a Cyclically Adjusted Book per Share of $3.43 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Arrowhead Pharmaceuticals' current Cyclically Adjusted Book per Share is $3.43. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share of $3.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Cyclically Adjusted Book per Share is $3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.13, compared to a current price of $79.62 — trading 52.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $3.43. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Cyclically Adjusted Book per Share is $3.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $79.62 is trading 52.7% above its estimated GF Value™ of $52.13. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Cyclically Adjusted Book per Share: $3.43
  • GF Value™: $52.13 vs. price of $79.62 (52.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.62
Price
$52.13
GF Value